-
ALSO READ
Dr Reddy's gets 5 observations from US FDA for API unit at Hyderabad Sun Pharma, Dr Reddy's, Glenmark gain even after price-fixing charges in US Dr Reddy's enters $ 71 mn market with launch of anti-allergy drug in US Dr Reddy's rallies after receiving EIR from USFDA Orchid Pharma shares go up 5% on rumours about prospective buyers -
Dr Reddy's Laboratories Limited and its subsidiary, Promius Pharma, LLC, on Monday announced the filing of new drug application (NDA) for its migraine candidate DFN-02 with the US Food and Drug Administration(US FDA).
DFN-02 is a novel intranasal spray formulation currently patented in 11 countries, composed of sumatriptan and permeation-enhancing technology known as Infravail of Aegis Therapeutics, LLC.
"The filing of DFN-02 represents our continuing commitment to bring innovative solutions in migraine treatment," said Anil Nmboodripad, senior vice president, proprietary products and president, Promius Pharma.
Upon approval, the product will be commercialised by Promius Pharma.
RECOMMENDED FOR YOU